Share on StockTwits
 

Investment analysts at Oppenheimer boosted their price objective on shares of Questcor Pharmaceuticals (NASDAQ:QCOR) from $90.00 to $99.00 in a note issued to investors on Wednesday, Analyst Ratings.Net reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s target price indicates a potential upside of 25.87% from the stock’s previous close.

In other Questcor Pharmaceuticals news, Director Broadwood Partners Lp unloaded 306,400 shares of Questcor Pharmaceuticals stock on the open market in a transaction dated Thursday, February 20th. The stock was sold at an average price of $74.94, for a total value of $22,961,616.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

A number of other firms have also recently commented on QCOR. Analysts at CRT Capital raised their price target on shares of Questcor Pharmaceuticals from $61.00 to $72.00 in a research note on Wednesday. They now have a “fair value” rating on the stock. Separately, analysts at Piper Jaffray raised their price target on shares of Questcor Pharmaceuticals from $85.00 to $98.00 in a research note on Wednesday. They now have an “overweight” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Questcor Pharmaceuticals from $76.00 to $89.00 in a research note on Wednesday. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $84.00.

Questcor Pharmaceuticals (NASDAQ:QCOR) traded down 3.34% during mid-day trading on Wednesday, hitting $76.02. 2,171,258 shares of the company’s stock traded hands. Questcor Pharmaceuticals has a one year low of $26.80 and a one year high of $80.25. The stock has a 50-day moving average of $64.63 and a 200-day moving average of $61.81. The company has a market cap of $4.477 billion and a P/E ratio of 18.06. Questcor Pharmaceuticals also saw some unusual options trading on Tuesday. Stock investors bought 11,353 put options on the company. This is an increase of 377% compared to the average volume of 2,380 put options.

Questcor Pharmaceuticals (NASDAQ:QCOR) last announced its earnings results on Tuesday, February 25th. The company reported $1.67 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.66 by $0.01. The company had revenue of $243.00 million for the quarter, compared to the consensus estimate of $244.15 million. On average, analysts predict that Questcor Pharmaceuticals will post $5.47 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Friday, April 25th. Investors of record on Friday, April 18th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 1.53%. The ex-dividend date of this dividend is Tuesday, April 15th.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.